Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Werewolf TherapeuticsHOWL -4.02%32 EV-to-EBITDA is 0.13 as of Aug. 10, 2026, which is 160% above its 10-year median of 0.05. GuruFocus rates HOWL with a GF Score™ of 32/100 and a GF Value™ of $3.78 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 400 Biotechnology companies, Werewolf Therapeutics ranks better than 94.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Werewolf Therapeutics's enterprise value is $-3.42 Mil.
Werewolf Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-26.41 Mil. Therefore, Werewolf Therapeutics's EV-to-EBITDA for today is 0.13.
The historical rank and industry rank for Werewolf Therapeutics's EV-to-EBITDA or its related term are showing as below:
HOWL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.79 Med: 0.05 Max: 1.21
Current: 0.13
During the past 7 years, the highest EV-to-EBITDA of Werewolf Therapeutics was 1.21. The lowest was -5.79. And the median was 0.05.
HOWL's EV-to-EBITDA is ranked better than 94.5% of 400
companies
in the Biotechnology industry
Industry Median: 13.065
vs HOWL: 0.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Werewolf Therapeutics's PE Ratio (TTM) for today is calculated as:
Werewolf Therapeutics's share price for today is $0.382.
Werewolf Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Werewolf Therapeutics EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Werewolf Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Werewolf Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's EV-to-EBITDA falls into.
Werewolf Therapeutics's current Enterprise Value is $-3.42 Mil.
Werewolf Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics (HOWL) has a EV-to-EBITDA of 0.13 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Werewolf Therapeutics. This is 160% above median its historical median of 0.05. According to the industry distribution chart, Werewolf Therapeutics ranks #22 out of 400 companies in the Biotechnology industry, placing it in the top 5.5%.
Is Werewolf Therapeutics' EV-to-EBITDA too high?
Werewolf Therapeutics' current EV-to-EBITDA of 0.13 is 160% above median its 10-year median of 0.05. The Biotechnology industry median EV-to-EBITDA is 13.07. Werewolf Therapeutics' value of 0.13 is 99% below this industry median. Based on the distribution chart, Werewolf Therapeutics ranks #22 out of 400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Werewolf Therapeutics has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Werewolf Therapeutics' EV-to-EBITDA compare to CVM and MRKR?
According to the Biotechnology industry distribution chart, Werewolf Therapeutics ranks #22 out of 400 companies for EV-to-EBITDA. This places Werewolf Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.07. Werewolf Therapeutics' value of 0.13 is 99% below this benchmark. While the company's 10-year median is 0.05 vs. the industry median of 13.07, Werewolf Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.07, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Werewolf Therapeutics's current EV-to-EBITDA of 0.13 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Werewolf Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Werewolf Therapeutics's current EV-to-EBITDA is 0.13, which is 160% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Werewolf Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Werewolf Therapeutics (HOWL) is currently considered Possible Value Trap. The stock's GF Value™ is $3.78, compared to a current price of $0.38 — trading 89.9% below its estimated fair value. The current EV-to-EBITDA is 0.13, which is 160% above median its 10-year median of 0.05 and 99% below the Biotechnology industry median of 13.07. Werewolf Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Werewolf Therapeutics (HOWL), the current EV-to-EBITDA is 0.13 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Werewolf Therapeutics (HOWL) Overvalued in 2026?
Based on GuruFocus' analysis, Werewolf Therapeutics stock appears to be undervalued.
The current stock price of $0.38 is trading 89.9% below its estimated GF Value™ of $3.78.
GuruFocus considers Werewolf Therapeutics to be Possible Value Trap.
Key valuation signals for HOWL:
EV-to-EBITDA: 0.13 (160% above median its 10-year median of 0.05)
GF Value™: $3.78 vs. price of $0.38 (89.9% below fair value)
Industry Position: 99% below the Biotechnology median (#22 of 400)
No single metric tells the full story. See the HOWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
32GF Score
Get the complete analysis for HOWL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOWL has been successfully added to your 
